Glentham Life Sciences wins a Queen’s Award for Enterprise 2021
We have been honoured with our second award in the International Trade category
COVID-19: Research & Candidates for Therapy
Here we list the products that are currently being investigated for effectiveness against COVID-19
16 March 2020
COVID-19: Research & Candidates for Therapy
There are a number of research products supplied by Glentham Life Sciences that are thought to have therapeutic potential against COVID-19, or could help to limit further spread of the SARS-CoV-2 virus.
The following products are all listed and sold by Glentham for research purposes, and can be delivered next-day across Europe and North America:
GP4306 - Camostat mesylate (59721-29-8)
GA7477 - Chloroquine diphosphate salt (50-63-5)
GP6351 - Lopinavir (192725-17-0)
GP1071 - Remdesivir (1809249-37-3)
GA5462 - Ribavirin (36791-04-5)
GP3714 - Ritonavir (155213-67-5)
We will continue to update this list as more potential candidates are highlighted to us.
Last updated: 16/03/20
Glentham acquires 22,000 sq. ft. facility in Corsham
Our new site in Corsham, Wiltshire, will add the facilities and warehouse space required to further our company’s expansion
Upcoming Exhibition: Bio Korea 2019 in South Korea
We are co-exhibiting at BIO KOREA on 17th - 19th April 2019, in Seoul, South Korea
Cookies
Our website uses cookies so that we can offer you the best possible browsing experience. This includes cookies that are essential for the normal operation of the website and non-essential cookies used for anonymous statistical purposes. By clicking Accept you will allow all cookies and full functionality of the website. If you click Decline, you will allow only essential cookies, however some features of the website may be impacted.